搜索
Jazz Pharmaceuticals PLC
JAZZ添加自选
252.860USD
-5.520-2.14%
收盘 07-31 16:00（美东）报价延迟15分钟
15.53B总市值
613.23市盈率 TTM
关于 Jazz Pharmaceuticals PLC 公司
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC简介
公司代码JAZZ
公司名称Jazz Pharmaceuticals PLC
上市日期Jan 18, 2012
CEOGala (Renee D)
员工数量2800
证券类型Ordinary Share
年结日Jan 18
公司地址Fifth Floor, Waterloo Exchange
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Ireland
邮编- -
电话35316347800
网址https://www.jazzpharma.com/
公司代码JAZZ
上市日期Jan 18, 2012
CEOGala (Renee D)
Jazz Pharmaceuticals PLC公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
常见问题
Jazz Pharmaceuticals PLC的前五大股东是谁？
Jazz Pharmaceuticals PLC 的前五大股东如下：Mr. Seamus C. Mulligan
有多少机构持有Jazz Pharmaceuticals PLC(JAZZ)的股份？
截至2026Q1，共有1229家机构持有Jazz Pharmaceuticals PLC的股份，合计持有的股份价值约为70.31M，占公司总股份的112.06%。与2025Q4相比，机构持股有所增加，增幅为-754072.00。
哪个业务部门对Jazz Pharmaceuticals PLC的收入贡献最大？
在2026Q1，Xywav业务部门对Jazz Pharmaceuticals PLC的收入贡献最大，创收1.66B，占总收入的38.83%。